Victor J. Dzau, MD, is the President of the National Academy of Medicine (NAM), formerly the Institute of Medicine (IOM). In addition, he serves as Vice Chair of the National Research Council. Dr. Dzau is Chancellor Emeritus and James B. Duke Distinguished Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dr. Dzau was the Hershey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School’s Brigham and Women’s Hospital, as well as Bloomfield Professor and Chairman of the Department of Medicine at Stanford University.
Dr. Dzau is an internationally acclaimed physician scientist and leader whose work has improved health and medicine in the United States and globally. His seminal work in cardiovascular medicine and genetics laid the foundation for the development of the class of lifesaving drugs known as ACE inhibitors, used globally to treat hypertension and heart failure. Dr. Dzau pioneered gene therapy for vascular disease and was the first to introduce DNA decoy molecules in humans in vivo. His pioneering research in cardiac regeneration led to the Paracrine Hypothesis of stem cell action and his recent strategy of direct cardiac reprogramming using microRNA.
Dr. Dzau serves as the inaugural president of NAM, transitioning from Institute of Medicine, and leads a strategy of innovation, action and equity. At the NAM, he has designed and led important initiatives such as Vital Directions for Health and Health Care, the Action Collaborative on Countering the US Opioid Epidemic, the Action Collaborative on Clinician Well-Being and Resilience, the Human Genome Editing; Emerging Science, Technology and Innovation. Under his tenure, the NAM has advanced efforts to improve health equity and address racism throughout its programmatic activities, especially the Culture of Health Program. Most recently, the NAM launched a Grand Challenge in Climate Change and Human Health & Equity to reverse the negative effects of climate change on health and social equity by activating the entire biomedical community, communicating and educating the public about climate change and health, driving changes through research, innovation and policy, and leading bold action to decarbonize the health care sector.
He has worked tirelessly to engage with the global response to COVID-19 by providing leadership as a member of the Global Preparedness Monitoring Board, co-chair of the G20 Scientific Expert Panel on Global Health Security, Advisor to the G20 High Level Independent Panel on Financing and a principal of the ACT-Accelerator which includes COVAX, the global collaboration for accelerating the development, manufacture and equitable distribution of COVID-19 vaccines.
Back to Board of Directors and Officers